Clinical Trials Sponsored by Institute for Neurodegenerative Disorders

Total 166 results

Institute for Neurodegenerative Disorders

Terminated

Evaluation of [18F] PBR06 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (PBR06)

Multiple Sclerosis | Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I]CLINDE and SPECT as a Marker of Inflammation in Subjects With PD or AD and in Healthy Subjects (CLINDE)

Multiple Sclerosis | Parkinson Disease | Alzheimer Disease | Healthy Controls

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F] FMH3 and PET as a Marker of Histamine-3 Receptor Activity in Subjects With AD Compared w/ HC (FMH3)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F] FEPPA and PET Imaging as a Marker of Inflammation in Subjects With Neurological Conditions

Multiple Sclerosis | Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I] AV94 and SPECT in Subjects With Alzheimer Disease in Comparison to Healthy Subjects (AV94)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Safety and Efficacy of Positron Emission Tomography Imaging With MNI-513

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Brain Imaging Study in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer's Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Single Photon Emission Computed Tomography (SPECT) Imaging Study to Develop a Biomarker for Alzheimer's Disease

Alzheimer's Disease

United States
Institute for Neurodegenerative Disorders

Completed

The Study of the Impact of Disclosing Imaging Study Information to Trial Participants

Parkinson | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders

Completed

A Study of the Sense of Smell in Relatives of Parkinson's Disease Patients

Parkinson Disease | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I] AV51 and SPECT as a Marker of Beta-amyloid Protein Deposition in Subjects With Alzheimer Disease in Comparison to Healthy Subjects

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions (FPEB)

Parkinson Disease | Alzheimer Disease | Mild Cognitive Impairment | Fragile X Syndrome | Huntington Disease | Autistic Spectrum Disorders

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of 123-I Iodobenzovesamicol (IBVM) and SPECT Imaging of Healthy Subjects and Patients With Alzheimer Disease (IBVM001)

Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F]MK-9470 as a Brain Tracer of Cannabinoid-1 Receptor in Parkinson's Disease and Healthy Subjects (MK9470)

Parkinson Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I] MNI-340 and SPECT as a Marker of Beta-Amyloid Protein Deposition

Alzheimer's Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I]MNI-420 and SPECT as a Marker of the Adenosine A2a Receptor in PD, HD and Healthy Subjects. (MNI-420)

Parkinson Disease | Huntington Disease

United States
Institute for Neurodegenerative Disorders

Completed

Research Involving Subjects With Parkinson's Disease, Alzheimer Disease and Healthy Controls

Parkinson Disease | Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F]MPPF as a Brain Tracer of Serotonin Receptor 5HT1a (MPPF)

Parkinson Disease

United States
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F] PBR111 and PET as a Marker of Inflammation in Subjects With Neurological Conditions (PBR111)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders

Terminated

Evaluation of [123I] AV151 and SPECT in Subjects w/ AD in Comparison to Healthy Subjects (AV151)

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders
Biogen

Completed

Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients

Multiple Sclerosis

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Terminated

Assessment of the Effect of Sertaline on the Specific Binding of 123-I MZINT in Healthy Subjects (mZINT)

Depression

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Terminated

Evaluation of [123I] MNI-330 and SPECT as a Marker of Beta-amyloid Protein Deposition

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

A Study of Neurophysiologic Changes in Individuals With Parkinson's Disease

Parkinson's Disease | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Terminated

Assessment of the Biodistribution and Safety of 123-I MZINT in Healthy Subjects and Parkinson Disease Patients

Parkinson Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Evaluation of [123I] AV83 and SPECT in Patients With Alzheimer Disease in Comparison to Healthy Controls

Alzheimers Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

ALTROPANE® SPECT Imaging in Patients With Parkinson Disease

Parkinson Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558 (MNI-558)

Alzheimer Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Use of [123I] AV39 and SPECT Imaging as a Marker of Protein Disposition in Subjects With Alzheimer Disease Compared to Healthy Subjects

Alzheimers Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Evaluation of [123I] MNI-187 and SPECT in Patients With Alzheimers Disease in Comparison to Healthy Subjects

Alzheimers Disease

United States
Molecular NeuroImaging
Institute for Neurodegenerative Disorders

Completed

Evaluation of [18F]MNI-777 PET as a Marker of Tau Pathology in Subjects With Tauopathies Compared to Healthy Subjects

Alzheimer's Disease (AD) | Tauopathies | Parkinson's Disease (PD) | Progressive Supranuclear Palsy (PSP) | Chronic Traumatic Encephalopathy (CTE) | Frontal Temporal Dementia (FTD) | Pick's Disease

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Study of Individuals With Parkinson's Symptoms But in Whom There is Diagnostic Uncertainty

Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
Molecular NeuroImaging

Completed

Biodistribution and Safety of a Radiopharmaceutical in Healthy Subjects

Neurodegenerative Diseases

United States
Institute for Neurodegenerative Disorders
GE Healthcare; Pfizer

Completed

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Density in Subjects With Parkinson's Disease

Parkinson Disease | Parkinsonian Syndrome

Spain, Austria, Germany, Italy
Michael J. Fox Foundation for Parkinson's Research
Institute for Neurodegenerative Disorders

Recruiting

PPMI Clinical - Establishing a Deeply Phenotyped PD Cohort (PPMI)

Parkinson Disease

United States, Canada, Spain, Israel, Austria, Germany, Greece, Italy, Netherlands, Nigeria, United Kingdom, Luxembourg
Michael J. Fox Foundation for Parkinson's Research
Institute for Neurodegenerative Disorders

Completed

PPMI Tau PET Imaging

Parkinson Disease

United States
Institute for Neurodegenerative Disorders
Alzheimer's Association; Molecular NeuroImaging

Completed

Assess 123-I IMPY and SPECT Imaging as a Tool to Detect β-Amyloid in the Brain

Alzheimer Disease

United States
Institute for Neurodegenerative Disorders
United States Department of Defense

Completed

Long-Term Dopamine Transporter Imaging and Clinical Assessment of Parkinson's Disease Progression (ELLDOPA)

Parkinson Disease
Institute for Neurodegenerative Disorders
United States Department of Defense

Completed

Assessing Imaging as a Tool in Monitoring and Predicting the Progression of Parkinson Disease

Parkinson Disease

United States
Molecular NeuroImaging
Roche Pharma AG; Institute for Neurodegenerative Disorders

Completed

Quantitative Evaluation of [18F]T807 as a Potential PET Radioligand for Imaging Tau in Patients With Alzheimer's Disease

Alzheimer's Disease (AD)

United States
Institute for Neurodegenerative Disorders
United States Department of Defense

Completed

Evaluation of 5-[123I]-A-85380 and SPECT Imaging in Individuals With Parkinsons Disease

Parkinson Disease

United States
Institute for Neurodegenerative Disorders
Indiana University; Albany Medical College

Completed

A Study of Brain Imaging With Nuclear Medicine Technology in Individuals With and at Risk for Parkinson's Disease

Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
National Institutes of Health (NIH); Molecular NeuroImaging

Completed

Study of Brain Imaging With Nuclear Technology in Individuals With Parkinsonian Syndrome

Parkinson's Disease | Parkinsonian Syndrome
Ken Marek, MD
Institute for Neurodegenerative Disorders

Completed

Study to Identify Clinical, Imaging and Biologic Markers of Parkinson Disease Progression (PPMI)

Parkinson Disease

United States, Spain, Israel, Norway, Germany, Italy, United Kingdom, France, Austria, Australia, Greece
Institute for Neurodegenerative Disorders
United States Department of Defense; Boehringer Ingelheim

Completed

Study of the Effects of Dopaminergic Medications on Dopamine Transporter Imaging in Parkinson's Disease

Parkinson Disease | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
United States Department of Defense; Molecular NeuroImaging

Completed

Development of Imaging, Clinical and Biochemical Bio-Markers for Parkinson's Disease

Parkinson's Disease | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
United States Department of Defense; Molecular NeuroImaging

Active, not recruiting

A Study Evaluating Potential Screening Tools for Detecting Parkinson Disease

Parkinson Disease

United States
Institute for Neurodegenerative Disorders
United States Department of Defense; Molecular NeuroImaging

Completed

Imaging and Genetic Biomarkers of Parkinson Disease (PD) Onset and Progression in High-risk Families

Parkinson Disease | Parkinsonian Syndrome

United States
Institute for Neurodegenerative Disorders
United States Department of Defense; University of Oklahoma

Completed

Development of Cognitive Assessment Tools in Parkinson Disease (ANAM)

Parkinson Disease

United States
University of Rostock
DZNE, German Center for Neurodegenerative Disorders, Germany

Unknown

Effect of Cognitive Intervention in Alzheimer's Disease (AD) on Functional Cortical Networks in fMRI (ECIF)

Dementia of the Alzheimer Type

Germany

Clinical Trials Sponsored by Institute for Neurodegenerative Disorders

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Tanzania

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations